Predictors of infusion reactions during infliximab treatment in patients with arthritis

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Kapetanovic, Meliha C ^a   Larsson, Lotta ^a   Truedsson, Lennart ^a   Sturfelt, Gunnar ^a   Saxne, Tore ^a   Geborek, Pierre ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PREDICTIVE VALUE; RISK; RISK FACTOR; SPONDYLARTHROPATHIES; STATISTICAL MODEL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SPONDYLARTHROPATHIES;

EID: 34548667692     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2020     Document Type: Article

References (21)

1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999, 354 1932-1939.
2. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
3. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica- Ihle E, Kellner H, Krause A, Schneider M, et al.: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
4. Brandt J, Braun J: Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther 2006, 6:99-107.
5. Cheifetz A, Mayer L: Monoclonal antibodies; immunogenicity; and associated infusion reactions. Mt Sinai J Med 2005, 72 250-256.
6. Baert F, Noman M, Vermeire S, Assche GV, Haens GD, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348 601-608.
7. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
8. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D: Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005, 38:155-160.
9. Rycke LD, Baeten D, Kruithof E, Bosch FV, Veys EM, Keyser FD: The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: Biological and clinical implications Lupus 2005, 14:931-937.
10. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005, 64:403-407.
11. Paulus HE, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK: Autoantibodies in early seropositive rheumatoid arthritis; before and during disease modifying antirheumatic drug treatment. J Rheumatol 2002, 29:2513-2520.
12. Ferraccioli GF, Nervetti A, Mercadanti M, Cavaliri F: Serum IgA levels and ANA behaviour in rheumatoid patients with and without toxicity to remission-inducing drugs. Clin Exp Rheumatol 1986, 4:217-220.
13. Schmidt KL, Mueller-Eckhardt C, Breithaupt H: HLA-B27; antinuclear antibodies and drug-induced agranulocytosis. Klin Wochenschr 1978, 56:1189-1191.
14. Panayi GS, Wooley P, Batchelor JR: Genetic basis of rheumatoid disease: HLA antigens; disease manifestations; and toxic reactions to drugs. Br Med J 1978, 2:1326-1328.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
16. der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
17. Moll JMH, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78.
18. Geborek P, Crnkic M, Petersson IF, Saxne T: Etanercept, infliximab and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798.
19. Fransen J, van Riel PL: The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005, 23(5 Suppl 39):S93-S99.
20. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger AH: Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000, 124:71-81.
21. Kapetanovic MC, Geborek P, Saxne T, Larsson L, Kristensen L, Svenson M, Bendtzen K: Development of antibodies against infliximab during infliximab treatment in rheumatoid arthritis. Relation to infusion reactions and treatment response [abstract 1440]. Arthritis Rheum 2005, 52 (Suppl):s543.